Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BIVI
stocks logo

BIVI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast BIVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIVI is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast BIVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIVI is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.610
sliders
Low
12.00
Averages
12.00
High
12.00
Current: 1.610
sliders
Low
12.00
Averages
12.00
High
12.00
Brookline
NULL -> Buy
maintain
$6 -> $12
2025-08-29
Reason
Brookline
Price Target
$6 -> $12
2025-08-29
maintain
NULL -> Buy
Reason
Brookline adjusted the firm's price target on BioVie to $12 from $6 and keeps a Buy rating on the shares. The firm cites the company's recent 1-for-10 reverse stock split for the target adjustment. It believes BioVie's cash position provides a runway through fiscal 2026.
See All Ratings

Valuation Metrics

The current forward P/E ratio for BioVie Inc (BIVI.O) is 0.00, compared to its 5-year average forward P/E of -2.89. For a more detailed relative valuation and DCF analysis to assess BioVie Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.89
Current PE
0.00
Overvalued PE
0.32
Undervalued PE
-6.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BIVI News & Events

Events Timeline

(ET)
2025-08-07
20:47:48
BioVie 6M share Secondary priced at $2.00
select
2025-07-24 (ET)
2025-07-24
08:19:29
BioVie presents data on Bezisterim at WCAG-2025
select
2025-07-22 (ET)
2025-07-22
08:08:09
BioVie appoints Amy Chappell, Kameel Farag to board of directors
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
11-21NASDAQ.COM
Biotech Stocks Fluctuate Post-Market: Delcath Gains from Buyback, BioVie and Cassava Recover

  • Delcath Systems' Buyback Announcement: Delcath Systems saw a 4.02% increase in after-hours trading to $8.52 following the announcement of a $25 million share repurchase program, indicating confidence in its long-term outlook.

  • BioVie Inc. Gains Despite No News: BioVie Inc. rose 13.39% to $1.44 in extended trading, rebounding from a decline during the regular session, with the increase attributed to speculative trading rather than new company-specific news.

  • Cassava Sciences' After-Hours Rally: Cassava Sciences advanced 9.17% to $2.87 after hours, recovering from a regular session drop, as investors reacted to its recent Q3 results showing a reduced net loss and significant cash reserves.

  • Enlivex Therapeutics' Modest Increase: Enlivex Therapeutics experienced a 4.24% rise to $0.95 in after-hours trading, despite no new developments reported on Thursday.

[object Object]
Preview
1.0
11-19Newsfilter
Participate in Biovie's Exclusive Live Investor Webinar and Q&A on December 9

  • Webinar Announcement: BioVie Inc. is hosting a webinar on December 9, 2025, featuring CEO Cuong Do, who will discuss the company's drug candidate bezisterim and its potential in treating neurological diseases and liver complications.

  • Drug Development Focus: Bezisterim targets inflammation and insulin resistance linked to Alzheimer's, Parkinson's, and Long COVID, while BIV201 is an orphan drug candidate for refractory ascites, currently in late-stage clinical development.

  • Market Potential: BioVie is advancing multiple late-stage clinical programs with promising safety data and significant market opportunities, positioning the company for potential value creation through upcoming milestones and partnerships.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding the company's expectations and potential risks, emphasizing that actual results may differ from projections due to various factors.

[object Object]
Preview
7.0
10-09Globenewswire
BIOVIE UPDATE: Bragar Eagel & Squire, P.C. Investigates BioVie Inc. for Long-Term Shareholders and Urges Investors to Reach Out to the Firm

  • Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against BioVie Inc. (BIVI) for long-term stockholders who may have suffered losses between August 5, 2021, and November 29, 2023, following a class action complaint regarding breaches of fiduciary duties by the company's board.

  • Clinical Trial Issues: BioVie disclosed significant protocol deviations and Good Clinical Practice violations in its Phase 3 clinical trial for NE3107, leading to a 60% drop in share price after the trial failed to achieve statistical significance due to the exclusion of patients from the trial.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is BioVie Inc (BIVI) stock price today?

The current price of BIVI is 1.61 USD — it has increased 1.26 % in the last trading day.

arrow icon

What is BioVie Inc (BIVI)'s business?

BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.

arrow icon

What is the price predicton of BIVI Stock?

Wall Street analysts forecast BIVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIVI is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is BioVie Inc (BIVI)'s revenue for the last quarter?

BioVie Inc revenue for the last quarter amounts to -5.28M USD, increased 41.98 % YoY.

arrow icon

What is BioVie Inc (BIVI)'s earnings per share (EPS) for the last quarter?

BioVie Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for BioVie Inc (BIVI)'s fundamentals?

The market is revising No Change the revenue expectations for BioVie Inc. (BIVI) for FY2026, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -7.47%.
arrow icon

How many employees does BioVie Inc (BIVI). have?

BioVie Inc (BIVI) has 13 emplpoyees as of December 05 2025.

arrow icon

What is BioVie Inc (BIVI) market cap?

Today BIVI has the market capitalization of 12.14M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free